Editorial · 2012
Conference abstractPublished 15 Apr 2013
Anti-VEGF treatment increases survival rate in high-risk corneal grafts
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Our objective was to improve high-risk corneal graft survival rate by bevacizumab treatment following combined surgery: penetrating keratoplasty (PK) +/- amniotic membrane (AMT) +/- limbal stem-cell transplantation (LCAT). Fifty high-risk eyes were included: 13 had rejected graft; 12 post-herpetic and 13 other vascularized scars, 6 chemical burns, 4 ulcers and 2 Steven-Johnson syndrome. All patients underwent combined surgery ended by subconjunctival bevacizumab injection (25 mg/ ml). Topical bevacizumab (2.5%) was delivered 3-4 times a day postoperatively. Grafts were prospectively (2 years) examined for clearance and presence of neovascularization (NV). Average endothelial cell loss was 22.83% after one, and 31.97% after two years (similar in all groups). Mean best corrected visual acuity had statistically significant increase in all groups from 0.03 to 0.5, with the poorest visual outcome in SJS patients.VEGF levels in recipient corneal buttons were analyzed by ELISA (R&D, USA) and real time PCR analysis. 82.5% of corneal grafts remained clear at the end of the observation period. Corneal NV was reduced in 87,5% of eyes. Recipient corneal buttons of high-risk patients secreted higher levels of VEGF (2436.74 pg/ml) as compared to keratoconus (504.7 pg/ml, p< 0.05). Marginal statistical significance was found in VEGFR1 with a tendency toward the up regulated VEGFR1 expression (p=0.052). Conclusions: Combination of subconjunctival and topical bevacizumab may offer an adjunctive measure to conventional treatment in high-risk patients. This might be explained by suppression of the angiogenic potential mediated by VEGF in such patients.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Case report · 2017
Long-Term Follow Up of Intra-Retinal Fluid and Outer Retinal Tubulations in a Case of Choroidal Osteoma Following Anti-VEGF Treatment
Conference abstract · 16 May 2016
The Course of Wet AMD Following phacoemulcification in Eyes Receiving Anti-VEGF Treatment
Conference abstract · 4 Aug 2015
Anti-VEGF in the treatment of diabetic macular oedema: A departmental study
Editorial · 2014
Retinal Laser Therapy: Recent Unique Developments Behind the Brilliant Front Stage of Anti-VEGF Treatment
More from this journal
The newest in Journal of Clinical and Experimental Ophthalmology.
Research article · 6 Oct 2026
Visual performance of wavefront-shaping extended-depth-of-focus intraocular lenses in Japanese eyes after previous laser in situ keratomileusis
Short communication · 30 Aug 2026
Vision Science in the Modern Era: Integrating Neuroscience, Genetics, and Technology
Commentary · 3 Aug 2026
Emerging Frontiers in Experimental Ophthalmology: Innovations and Translational Challenges
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Iva Dekaris”

